The role of endothelin in the pathogenesis of heart failure
Current Cardiology Reports, ISSN: 1523-3782, Vol: 4, Issue: 3, Page: 206-212
2002
- 15Citations
- 6Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations15
- Citation Indexes15
- 15
- CrossRef11
- Captures6
- Readers6
Article Description
In fewer than than 15 years since its discovery, endothelin is now recognized as playing a central role in the pathogenesis of chronic heart failure. This review examines the signaling pathways and mechanism of action of endothelin in relation to the studies that have elucidated this role. Early investigations observed that the endothelin system is markedly upregulated in heart failure, whereas others demonstrated that endothelin is the most potent vasoconstrictor. However, it has multiple other actions, including mediating pathologic hypertrophy and fibrosis of both ventricular and vascular tissues, acting as a proarrhythmic, and potentiating the effects of other neurohormones. Endothelin receptor antagonists were developed to investigate the hypothesis that these adverse effects could be prevented and experimental studies showed promise in this regard. Clinical studies to date have not fulfilled this promise. Further analysis of these trials will hopefully provide insight into these disparate findings and guidance for future investigations. © 2002 by Current Science Inc.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0036584133&origin=inward; http://dx.doi.org/10.1007/s11886-002-0052-2; http://www.ncbi.nlm.nih.gov/pubmed/11960589; http://link.springer.com/10.1007/s11886-002-0052-2; http://www.springerlink.com/index/10.1007/s11886-002-0052-2; http://www.springerlink.com/index/pdf/10.1007/s11886-002-0052-2; https://dx.doi.org/10.1007/s11886-002-0052-2; https://link.springer.com/article/10.1007/s11886-002-0052-2
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know